University of South Florida

The United States Government As Represented by the Department of Veterans Affairs

Transgenex Nanobiotech Inc.

Other

The Johns Hopkins University

Transgenex Therapeutics, LLC

Shyam S Mohapatra

Subhra Mohapatra

Arun Babu Kumar

Mukesh Kumar

Tao Wang

Aruna K Behera

Eleni Markoutsa

Jia-Wang Wang

Rajesh R Nair

Alya Limayem

Weidong Zhang

Don F Cameron

Rasim Oytun Guldiken

Juan Sanchez-Ramos

Chunyan Wang

Shijie Song

Vasyl Sava

Hiroto Matsuse

Mark Howell

Bishwabhusan Sahoo

Kam W Leong

Paul R Sanberg

Susana Lai-Yuen

Alejandro J Gonzalez

Julio Garay

Dmitri V Voronin

Sharad Ambardar

Weidong Xu

Xiaoyuan Kong

Xiaoqin Wang

Mahasweta Das

Sumita Behera

Taylor Martinez

Shua-ku Huang

Yvonne Kathleen Davis

Christian Bernard Brechot

Nancy Lucrecia Goicochea

Suraj Dixit

Karthick Mayilsamy

Heta N Jadhav

Eleni Markousta

Srinivas Nagaraj Bharadwaj

Mark Glaum

Guoqing Liu

Kyle A Cissell

Subbiah Alwarappan

The present disclosure relates to exosomes isolated from mesenchymal stem cells exposed to a conditioned media in which microglial cells are cultured in the presence of lipopolysaccharide (LPS) or a beta-amyloid oligomer and uses thereof for reducing inflammation and for treating Alzheimer's disease.

Exosomes isolated from mesenchymal stem cells and uses thereof

Method for increasing efficiency of a pathogen inactivation via enhancing UVC light absorption at such pathogen by multiple diffuse scattering of the light at a wall defining a substantially closed volume, thereby increasing a number of angles at which the pathogen is being irradiate as compared with a direct irradiation of the pathogen with a beam of such light.

Ultrafast-UV laser integrating cavity mediated inactivation of a pathogen

This disclosure is directed to therapeutic compositions, and more particularly to microparticle compositions for the controlled delivery of telmisartan and actinomycin D.

Microparticle compositions for controlled delivery of telmisartan and actinomycin D

This invention provides for a RSV-targeted nanoparticle PMN (RTPMN), combining HR2D anti-fusion peptide, and plasmid encoded siRNA against RSV-NS1 and/or RSV-P gene as a safe, effective and inexpensive anti-RSV prophylaxis and/or therapy.

Compositions and methods for treating RSV-infections

A 4D-perfused tumoroid-on-a-chip platform used in personalized cancer treatment. The platform includes a plate with a plurality of bottomless wells that resides atop a microfluidic channel layer, which in turn resides atop a surface acoustic wave (SAW) based sensor layer that is capable of measuring potential pH values of fluids disposed within the platform. The microfluidic channel layer includes a plurality of bioreactors, with each bioreactor including an inlet well, a culture well, and an outlet well. The inlet well, culture well, and outlet well form a closed system via fluid conduits spanning from the inlet well to the culture well, as well as from the culture well to the outlet well. Due to the fluid flow from the plate to the chip, and from the inlet well to the outlet well on the chip through the culture well, target cell (tumoroid) growth is promoted within the culture well.

4D-perfused tumoroid-on-a-chip platform for personalized cancer treatment applications

A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-&#x3b3; agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-&#x3b2;, and TNF&#x3b1;, which have been associated with SARS-CoV-2 infection.

Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19

A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and/or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.

Method of delivering genes and drugs to a posterior segment of an eye

The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.

Method of targeting oncolytic viruses to tumors

An in vitro microfluidic device includes a device configured to model a blood-brain barrier. The device includes a center well in fluidic communication with each of an inlet and an outlet. Each of the center well, inlet, and outlet includes a porous membrane that separates a 'blood' portion (a fluid flow portion) from a 'brain' portion (a fluid containing portion). The porous membrane is seeded with endothelial cells such as the human venule endothelial cells (HUVECs) on the blood side, and with astrocytes on the brain side, to accurately model the blood-brain barrier. Fluid flows between the inlet, the center well, and the outlet to test the permeability of the porous membrane, thereby providing an accurate in vitro model of a blood-brain barrier.

Microfluidic-coupled in vitro model of the blood-brain barrier

A novel SH-SAW biosensor capable of non-invasive and touch-free detection of cancer cell viability and growth or proliferation in two-dimensional (2D) and three-dimensional (3D) cell cultures as well as stem cell regeneration as it pertains to cancer cell biology and anti-cancer drug development is presented. The biosensor includes two pairs of resonators including interdigital transducers reflecting fingers to quantify mass loading by the cells in suspension as well as within a tumoroid culture platform. The biosensor can be part of a perfused 3PNS-tumoroid system that is amenable to real-time non-invasive monitoring of the cell proliferation, viability, and multiplexed detection of key physiologic and clinical biomarkers.

System and method of measuring cell viability and growth

Disclosed herein are compositions and methods for treating cancer. Further provided herein are compositions and methods for reducing, inhibiting, or preventing resistance of cancer to tyrosine kinase inhibitors. The methods may include administering an anti-resistance agent such as a CYP51A1 inhibitor or an agonist of miRNA-764 (SEQ ID NO: 4) to a subject. A tyrosine kinase inhibitor may also be administered to the subject in addition to the anti-resistance agent.

Methods and compositions for treating drug resistance in cancer

A broad-based remediation mechanism against MRFs and alternative fecal indicators such as multidrug resistant, including nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. The current invention relates to mitigation of drug resistant bacteria, for example in hospitals and in food animals, and to the identification. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The invention also relates to the treatment of multi-drug resistant biofilms which mimic in vivo conditions. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRF and alternative resistant strain-induced illnesses without compromising the balance of the beneficial flora in the physiological and ecological microenvironments. The combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in treating multi-drug resistant pathogens.

Chitosan oligomer and zinc oxide nanoparticle compositions for treating drug resistant bacteria and biofilm

A broad-based remediation mechanism against MRFs and alternative fecal indicators such as multidrug resistant, including nanotechnology formulations and methodologies that may be used to develop novel treatment strategies against certain drug resistant bacterial strains. The current invention relates to the treatment of drug resistant bacteria from nosocomial infections, for example in hospitals and in food animals. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively treat multi-drug resistant bacteria without compromising the balance of the beneficial flora in the physiological and ecological microenvironments in a host. Also, the combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in remediation of important food-borne bacteria including the resistant types.

Chitosan zinc oxide nanoparticle formulation for treating drug resistant bacteria

Growing community of inventors

Lutz, FL, United States of America

Shyam S Mohapatra